Shares of Sun Pharmaceutical Industries on Sunday ended nearly 1 per cent higher after the firm posted a 16 per cent increase in its consolidated net profit for the third quarter ended December 31, 2025.
The stock ended at ₹1,610.20, up 0.95 per cent on the BSE. During the day, it climbed 3.81 per cent to ₹1,655.80.
At the NSE, the stock advanced 0.92 per cent to end at ₹1,610.10. During the day, it edged higher by 3.78 per cent to ₹1,655.70.
Sun Pharmaceutical Industries on Saturday posted a 16 per cent increase in its consolidated net profit to ₹3,369 crore for the third quarter ended December 31, 2025, led by growth across business segments.
The Mumbai-based drug major reported a net profit of ₹2,903 crore for the October-December quarter of last fiscal.
Total revenue from operations rose to ₹15,520 crore for the third quarter as against ₹13,675 crore in the year-ago period.
The company said its board has approved an interim dividend of ₹11 per equity share of Re 1 for the financial year 2025-26.
“Our results this quarter demonstrate well-rounded growth across all businesses, prominently led by our branded businesses in India, emerging markets and global innovative medicines,” Sun Pharma MD Kirti Ganorkar said in a statement.
Published on February 1, 2026